🎯 Background & Rationale
Robotic-assisted bronchoscopy (RAB) platforms (specifically the Ion and Monarch systems) have become ubiquitous for sampling peripheral pulmonary nodules. Despite their widespread adoption, a head-to-head comparison evaluating performance differences in procedural safety and diagnostic yield between these two major platforms had not been investigated, as most prior data stem from platform-specific studies with inconsistent definitions of diagnostic yield.
👥 Study Design & Population
- Study Type: Retrospective, 2-site cohort study.
- Population: 217 adult patients (122 in the Ion group at UPMC; 95 in the Monarch group at VA Pittsburgh) undergoing outpatient or inpatient RAB for peripheral pulmonary nodules between August 2020 and August 2023.
- Intervention: Robotic-assisted bronchoscopy performed using either the Ion or Monarch platform, assisted by standard 2D fluoroscopy (cone-beam CT and cryobiopsy were not available).
📈 Methodology & Rigor
The authors utilized an unadjusted logistic regression model, a parsimonious adjusted model (controlling for nodule size, bronchus sign, and the Brock University cancer prediction score), and an exploratory model with additional covariates (age, smoking status, spiculations). Rigorous sensitivity analyses were performed, including excluding the initial 20 cases for each platform, restricting the cohort to patients with a completed PET scan, and nearest-neighbor matching via Mahalanobis distance. A strict, consensus-based definition of diagnostic yield was applied, and all nondiagnostic cases underwent 24-month clinical/radiographic follow-up.
🔬 Key Findings [or Planned Endpoints]
- Diagnostic Yield: The overall cohort diagnostic yield was 56% (Ion group: 53%; Monarch group: 46%). Sub-centimeter nodules (20% of the cohort) had a yield of 35%.
- Platform Comparison: Neither the unadjusted, parsimonious, nor exploratory models showed a statistically significant difference in diagnostic yield between the Ion and Monarch platforms (Parsimonious OR: 1.5 [0.9–2.7], $P=0.15$). A small advantage for Ion was noted only in the nearest-neighbor matched sensitivity analysis.
- Predictors of Success: Nodule size [OR: 1.42 (1.09–1.86)] and the presence of a bronchus sign [OR: 2.14 (1.14–4.01)] correlated positively with diagnostic yield.
- Safety: Complications were exceedingly rare across both platforms, with only 2 direct pneumothoraces (1%) and grade 4 bleeding occurring in 1% of patients.
⚖️ Critical Appraisal
The study's strengths include its head-to-head design utilizing operators credentialed on both platforms, a conservative consensus-based definition of diagnostic yield, and a 24-month follow-up. Limitations include its retrospective nature, reliance on medical record documentation (which lacked granular data on biopsy tool order, precise pass counts, and radial EBUS use), and baseline demographic/clinical differences between the two hospital sites (VA vs. university hospital). Furthermore, the lack of advanced imaging modalities like cone-beam CT limits generalizability to centers utilizing modern imaging-integrated workflows.
💡 The Clinical Bottom Line
In the absence of advanced imaging adjuncts (like cone-beam CT), there is no significant difference in diagnostic yield or safety profile between the Ion and Monarch robotic bronchoscopy platforms. Proceduralists should recognize that nodule size and the presence of a bronchus sign remain the primary drivers of procedural success, and low-complexity fluoroscopic RAB achieves safe, acceptable real-world yields when sampling small peripheral pulmonary lesions.